Revolutionary needle-free epinephrine achieves $15.7M quarterly revenue with accelerating market adoption ARS Pharmaceuticals delivered exceptional Q2 2025 results with $15.7 million in total revenue, including
Canadian biotech advances RESOLVE Phase 2b trial for gastrointestinal indications with topline data expected H2 2026 Eupraxia Pharmaceuticals announced Q2 results and achieved a significant
First-ever Phase 3 study in HPV16-positive head and neck cancer demonstrates strong enrollment progress PDS Biotech reported Q2 results alongside significant progress in its groundbreaking
President Trump to discuss policies boosting domestic drug production and innovation investment The White House announced plans for President Trump to meet with pharmaceutical industry
Voluntary early-review initiative shifts to preventive manufacturing quality oversight The FDA launched a new “Pre-Check” voluntary program allowing pharmaceutical manufacturers to undergo proactive quality systems
Senior credit facility supports Afrezza pediatric launch, commercial expansion, and pipeline advancement MannKind Corporation secured up to $500 million in a senior credit facility from
Inflammatory disease biotech pursues unprecedented combination of drug development and Ethereum treasury management In an unusual move for biotechnology, 180 Life Sciences announced a massive
Inflammatory disease biotech pursues unprecedented combination of drug development and Ethereum treasury management In an unusual move for biotechnology, 180 Life Sciences announced a massive
Series B funding supports programmable mRNA platform with lead candidate showing promise in solid tumors Massachusetts-based Strand Therapeutics completed a $153 million Series B financing
Multi-year partnership leverages AI analytics to improve treatment outcome modeling AstraZeneca expanded its collaboration with health data firm SOPHiA GENETICS to harness AI-powered “Multimodal Analytics
